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Background: Secukinumab improved signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).
1,2
Objectives: To report the efficacy and safety of secukinumab over 3 years from the MEASURE 2 study. Methods: 219 patients (pts) with active AS were randomised to subcutaneous secukinumab 150mg (72 pts), 75mg (73 pts) or placebo (PBO, 74 pts). At Week (Wk) 16, PBO treated pts were re-randomised 1:1 to secukinumab 150mg or 75mg, irrespective of clinical response. Pts initially randomised to secukinumab and those who switched from PBO to secukinumab at Wk 16 were included in the analysis (secukinumab 150mg, N=106 and secukinumab 75mg, N=105). Outcome measures at Wk 156 included ASAS20 and 40, ASDAS-CRP inactive disease, ASAS5/6, BASDAI, SF-36 PCS and ASAS partial remission. Data are reported as observed. Safety analyses included all pts who received ≥1 dose of secukinumab. Results: At 156 wks, the completion rates for secukinumab 150mg was 81.1% (86/106) and 72.4% (76/105) for 75mg. Higher discontinuation rates for 75mg were in part due to lack of efficacy or patient/guardian decision. Efficacy observed across endpoints from Wks 52 to 156 are summarised in the Table. Higher responses were observed in the 150mg group (Table and Figure) . Over the entire study period, the mean exposure [±SD] to secukinumab was 914.3±315.5 days. The exposure-adjusted incidence rates with Any secukinumab for infections/infestations, Crohn's disease, malignant/unspecified tumours and major adverse cardiovascular events were 1.5, 0.6, 0.6 and 0.6 per 100 pt-years, respectively. Conclusions: Secukinumab 150mg provided sustained improvement in the signs & symptoms along with physical functions with over 80% retention rate through 3 years in pts with AS. Safety profile remained favourable and was consistent with previous reports. Objectives: The aim of the study was to evaluate the changes in concentration of interleukin-17A (IL-17A) in patients with AS, treated with tumor necrosis factor α inhibitors (anti-TNFα) during the year. Methods: 30 patients with AS, fulfilled m. New-York criteria, with BASDAI ≥4.0 and NSAIDs non-responders were involved in the study. Mean age of AS patients at baseline was 38.35±9.19 years (M ± SD), the duration of AS was 11.4±9.6 years, 22 (73.3%) of patients -male. 20 healthy volunteers were involved as controls (mean age 40.1±7.7 years, male -12 (60%). All AS patients were treated during the year with Remicade (infliximab, MSD ® )) -5 mg/kg at the recommended scheme. BASDAI, ASDAS CRP indices were calculated, C-RP, TNFα and IL-17A levels were measured before the treatment with anti-TNFα (baseline) and 52±2 weeks after the baseline. Number of patients achieved ASAS 20, ASAS 40 responses, and ASAS partial remission was evaluated. The statistics was performed with SPSS17. Results: Baseline concentrations of TNFα and IL-17A in AS patients were higher than in healthy subjects (28.4±14.4 and 2.4±2.1, respectively, p<0.000). Significant reduction of AS activity, but not of IL-17A serum concentration was marked at week 52, Table 1 . 24 (80%) achieved ASAS 20, 18 (60%) -ASAS 40, 12 (40%) of patients with
